Novavax has published the first pre-clinical study report of its Pandemic 2009 H1N1 influenza virus-like particle (VLP) vaccine.

Novavax and the Centres for Disease Control and Prevention (CDC) co-authored the report, which confirmed the H1N1 influenza VLP vaccine was highly immunogenic in trials conducted on ferrets.

Animals immunised with a 15mcg dose of the vaccine had no detectable virus recovered in nasal washes and there were no signs of the disease.

Novavax and the CDC scientists’ scientific report concludes that effective immunity to the H1N1 pandemic virus can be achieved in ferrets by the vaccination, resulting in significant protection and viral clearance from the upper and lower respiratory tracts